Biocardia Net Income
| BCDA Stock | USD 1.16 0.05 4.13% |
As of the 4th of February, Biocardia shows the Standard Deviation of 3.47, risk adjusted performance of (0.02), and Mean Deviation of 2.55. Biocardia technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Biocardia Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.1 K | Earnings Share (1.42) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.2 M | -6.8 M | |
| Net Loss | -7.2 M | -7.5 M | |
| Net Loss | -10.7 M | -11.3 M | |
| Net Loss | (2.61) | (2.74) | |
| Net Income Per E B T | 1.15 | 1.29 |
Biocardia | Net Income | Build AI portfolio with Biocardia Stock |
Analyzing Biocardia's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Biocardia's current valuation and future prospects.
Latest Biocardia's Net Income Growth Pattern
Below is the plot of the Net Income of Biocardia over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Biocardia financial statement analysis. It represents the amount of money remaining after all of Biocardia operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Biocardia's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocardia's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.95 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Biocardia Net Income Regression Statistics
| Arithmetic Mean | (6,684,508) | |
| Coefficient Of Variation | (107.39) | |
| Mean Deviation | 5,974,664 | |
| Median | (7,946,000) | |
| Standard Deviation | 7,178,301 | |
| Sample Variance | 51.5T | |
| Range | 24.7M | |
| R-Value | (0.65) | |
| Mean Square Error | 31.4T | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | (930,861) | |
| Total Sum of Squares | 824.4T |
Biocardia Net Income History
Other Fundumenentals of Biocardia
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Biocardia Net Income component correlations
Biocardia Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Biocardia is extremely important. It helps to project a fair market value of Biocardia Stock properly, considering its historical fundamentals such as Net Income. Since Biocardia's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biocardia's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biocardia's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value - what Biocardia's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Biocardia 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biocardia's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biocardia.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Biocardia on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Biocardia or generate 0.0% return on investment in Biocardia over 90 days. Biocardia is related to or competes with Creative Medical, Aprea Therapeutics, Acurx Pharmaceuticals, Kiora Pharmaceuticals, HCW Biologics, Alzamend Neuro, and Adial Pharmaceuticals. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for car... More
Biocardia Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biocardia's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biocardia upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 21.46 | |||
| Value At Risk | (4.32) | |||
| Potential Upside | 5.93 |
Biocardia Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biocardia's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biocardia's standard deviation. In reality, there are many statistical measures that can use Biocardia historical prices to predict the future Biocardia's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.1) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biocardia's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Biocardia February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 2.55 | |||
| Coefficient Of Variation | (2,781) | |||
| Standard Deviation | 3.47 | |||
| Variance | 12.06 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.1) | |||
| Maximum Drawdown | 21.46 | |||
| Value At Risk | (4.32) | |||
| Potential Upside | 5.93 | |||
| Skewness | 0.2718 | |||
| Kurtosis | 1.72 |
Biocardia Backtested Returns
Biocardia secures Sharpe Ratio (or Efficiency) of -0.0344, which signifies that the company had a -0.0344 % return per unit of risk over the last 3 months. Biocardia exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Biocardia's Risk Adjusted Performance of (0.02), standard deviation of 3.47, and Mean Deviation of 2.55 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biocardia will likely underperform. At this point, Biocardia has a negative expected return of -0.11%. Please make sure to confirm Biocardia's skewness, day typical price, and the relationship between the treynor ratio and rate of daily change , to decide if Biocardia performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.62 |
Good predictability
Biocardia has good predictability. Overlapping area represents the amount of predictability between Biocardia time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biocardia price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Biocardia price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Biocardia Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Biocardia reported net income of (7.95 Million). This is 102.33% lower than that of the Biotechnology sector and 111.34% lower than that of the Health Care industry. The net income for all United States stocks is 101.39% higher than that of the company.
Biocardia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biocardia's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics of similar companies.Biocardia is currently under evaluation in net income category among its peers.
Biocardia Institutional Holders
Institutional Holdings refers to the ownership stake in Biocardia that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Biocardia's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biocardia's value.| Shares | Global Retirement Partners, Llc. | 2025-06-30 | 411 | Jpmorgan Chase & Co | 2025-06-30 | 234 | Advisor Group Holdings, Inc. | 2025-06-30 | 62.0 | Sbi Securities Co Ltd | 2025-06-30 | 6.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Cm Management, Llc | 2025-06-30 | 130 K | Susquehanna International Group, Llp | 2025-06-30 | 38.8 K | Geode Capital Management, Llc | 2025-06-30 | 37.5 K | Brown Advisory Holdings Inc | 2025-06-30 | 35.5 K | Cetera Investment Advisers | 2025-06-30 | 20.3 K | Commonwealth Equity Services Inc | 2025-06-30 | 18.1 K |
Biocardia Fundamentals
| Return On Equity | -3.17 | ||||
| Return On Asset | -0.86 | ||||
| Current Valuation | 8.19 M | ||||
| Shares Outstanding | 10.61 M | ||||
| Shares Owned By Insiders | 26.66 % | ||||
| Shares Owned By Institutions | 4.36 % | ||||
| Number Of Shares Shorted | 216.07 K | ||||
| Price To Earning | (11.00) X | ||||
| Price To Book | 4.89 X | ||||
| Price To Sales | 3,090 X | ||||
| Revenue | 58 K | ||||
| Gross Profit | (5.25 M) | ||||
| EBITDA | (7.93 M) | ||||
| Net Income | (7.95 M) | ||||
| Cash And Equivalents | 8.61 M | ||||
| Cash Per Share | 0.49 X | ||||
| Total Debt | 951 K | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 3.00 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (8.03 M) | ||||
| Short Ratio | 2.19 X | ||||
| Earnings Per Share | (1.42) X | ||||
| Target Price | 15.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 12.84 M | ||||
| Total Asset | 3.72 M | ||||
| Retained Earnings | (160.12 M) | ||||
| Working Capital | 301 K | ||||
| Current Asset | 19.48 M | ||||
| Current Liabilities | 330 K | ||||
| Net Asset | 3.72 M |
About Biocardia Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biocardia's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocardia using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocardia based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value - what Biocardia's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.